| Bioactivity | Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM[1]. | ||||||||||||
| Invitro | Valbenazine exhibits VMAT2 binding affinity in rat striatum and human platelets with Kis of 110 and 150 nM, respectively[1]. | ||||||||||||
| In Vivo | Valbenazine (10 mg/kg; orally) induces ptosis (primarily an adrenergic response) and increases plasma prolactin primarily a dopaminergic response in rats[1]. | ||||||||||||
| Name | Valbenazine | ||||||||||||
| CAS | 1025504-45-3 | ||||||||||||
| Formula | C24H38N2O4 | ||||||||||||
| Molar Mass | 418.57 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Dimitri E Grigoriadis, et al. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. J Pharmacol Exp Ther. 2017 Jun;361(3):454-461. |